We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Article from 2021-01-25
Over time, new variants of a virus are expected to occur as all viruses constantly mutate their genetic code. These variants can emerge and disappear spontaneously, though sometimes selective pressure allows the variant to persist through adaptive evolution. Multiple variants of the SARS-CoV-2 virus that causes COVID-19 have been documented globally. The first emerging concern was a variant originating in the United Kingdom with an unusually large number of mutations.
Lineage B.1.1.7 (known as Alpha, 20B/501Y.V1, or VOC 202012/01, which indicates the first variant of concern in December 2020) carries 23 mutations compared to the wild-type SARS-CoV-2. This includes 14 non-synonymous (amino acid altering) mutations, six synonymous (non-amino acid altering) mutations, and three deletions (Table 1).1,2 17 of these mutations lead to changes in protein structures, eight of which occur in the spike protein (Figure 1). This is highly unprecedented as most SARS-CoV-2 variants have only a few mutations that accumulate at a relatively consistent rate over time (~1-2 per month).
| Protein | Amino Acid |
| ORF1ab | T1001I |
| A1708D | |
| I2230T | |
| SGF 3675-3677 deletion | |
| C913T | |
| C5986T | |
| C14676T | |
| C15279T | |
| C16176T | |
| Spike | H69-V70 deletion |
| Y144 deletion | |
| N501Y | |
| A570D | |
| P681H | |
| T716I | |
| S982A | |
| D1118H | |
| ORF8 | Q27stop |
| R52I | |
| Y73C | |
| N | D3L |
| S235F | |
| M | T26801C |
Figure 1. Compilation of SARS-CoV-2 spike mutations occurring in the new UK, South African, Brazilian, and Indian variants as indicated in the inset.
NTD: N-terminal domain. RBD: Receptor binding domain.
One of the most important changes in B.1.1.7 is a mutation in the receptor binding domain (RBD) of the spike protein at position 501, where asparagine has been replaced with tyrosine (N501Y). According to prior work on variants with N501Y, this substitution is thought to increase the affinity of the spike protein for the angiotensin-converting enzyme 2 (ACE2) receptor on human cells, its entry point for infection.3 Indeed, the B.1.1.7 variant is estimated to be 74% more transmissible than the wild type and was projected to become the dominant source of infection in the US by March 2021.
Other notable mutations in the B.1.1.7 variant include a double deletion of the amino acids in positions H69-V70 in the N-terminal domain of the spike protein that likely leads to a conformational change in the spike protein. This particular mutation has also been found in coronaviruses that eluded the immune response in some immunocompromised patients and appeared in infected mink in Denmark in August 2020.4 A study from the University of Cambridge has suggested this mutation increases infectivity two-fold in in vitro experiments and may make neutralizing antibodies less effective.5
A P681H mutation occurs at one of the four residues that comprise the insertion that creates a furin cleavage site between S1 and S2 in the spike protein. This site, which facilitates viral membrane fusion to host cells, has been shown to promote entry into respiratory epithelial cells and transmission in animal models.6-8
The function of a stop codon (Q27stop) added to the open reading frame 8 (ORF8) that renders it inactive is not completely known and may allow further downstream mutations to accrue. This gene is hypervariable with a tendency to recombine and undergo deletions that facilitate viral adaptation to the human host. The ORF8 gene encodes for an immunoglobulin-like protein that was recently found to inhibit the presentation of viral antigens by class I major histocompatibility complex, suppress the type I interferon antiviral response, and interact with host factors involved in pulmonary inflammation and fibrogenesis.9 A full deletion of ORF8 in a variant identified in Singapore has been associated with milder COVID-19 symptoms and better disease outcome.10
In South Africa, another variant of SARS-CoV-2 (known as Beta, 20C/501Y.V2 or B.1.351 lineage) emerged independently of the B.1.1.7 lineage. This variant has eight defining mutations in the spike protein including K417N, E484K, and N501Y substitutions in the spike protein RBD that increase affinity for the ACE2 receptor (Table 2, Figure 1).11,12 Although it contains the N501Y mutation found in the B.1.1.7 variant, it does not contain the deletion at H69-V70. The E484K mutation has been associated with escape from neutralizing antibodies.13
| Protein | Amino Acid |
| Spike | L18F |
| D80A | |
| D215G | |
| L242_244L (disputed deletion) | |
| R246I | |
| K417N | |
| E484K | |
| N501Y | |
| A701V |
Circulating in the Brazilian Amazon region, a branch off the SARS-CoV-2 B.1.1.28 lineage termed P.1 (Gamma or 20J/501Y.V3) includes several mutations of known biological importance such as E484K, K417T, and N501Y in the RBD of the spike protein but is of independent origin from B.1.1.7 and B.1.351.14 This variant has ten defining mutations in the spike protein (Table 3, Figure 1).15 The B.1.1.28 variant was associated with two cases of reinfection in patients originally infected by the Brazilian B.1.1.33 lineage, and the P.1 variant was identified in Japan from travelers returning from northern Brazil.14,16
| Protein | Amino Acid |
| ORF1ab | SynT733C |
| SynC2749T | |
| S1188L | |
| K1795Q | |
| Del11288-11296 (SGF 3675-3677 deletion) | |
| SynC12778T | |
| SynC13860T | |
| E5665D | |
| Spike | L18F |
| T20N | |
| P26S | |
| D138Y | |
| R190S | |
| K417T | |
| E484K | |
| N501Y | |
| H655Y | |
| T1027I | |
| ORF8 | E92K |
| Ins28269-28273 | |
| N | P80R |
A variant from India, designated as B.1.617.2 or Delta, is now the predominant variant in the US, according to estimates by the CDC (Table 4, Figure 1). A structural analysis of B.1.617.2 RBD mutations (L452R along with P681R in the furin cleavage site) suggest that these mutations may result in increased ACE2 binding and rate of S1-S2 cleavage, resulting in better transmissibility and possible capacity to escape binding and neutralization by some monoclonal antibodies.17 A mutation of this variant, called Delta plus, has acquired the spike protein mutation K417N in the RBD that in other variants has been shown to increase affinity for the ACE2 receptor.
B.1.617.2 | |
| Protein | Amino Acid |
| Spike | T19R |
| G142D | |
| Del156-157 | |
| R158G | |
| L452R | |
| T478K | |
| D614G | |
| P681R | |
| D950N | |
The simultaneous emergence of different SARS-CoV-2 lineages from different countries around the world each carrying mutations in the spike protein receptor binding site reveal convergent selective pressure on SARS-CoV-2 to create an advantage towards its transmissibility and reinfection of individuals. This is a major concern as these mutations may evolve to escape neutralizing antibodies. Cayman is monitoring the rapidly emerging information on these variants and offers structure-based design services (SBDD) for macromolecular X-ray crystallography and computer-aided drug design services (CADD) for in silico screening of drug candidates that target the SARS-CoV-2 spike protein.
| |
|
1. Rambaut, A., Loman, N., Pybus, O., et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. In: virological.org [Internet]. (2020). Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
2. Gu, H., Chen, Q., Yang, G., et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369(6511), 1603-1607 (2020).
3. Starr, T.N., Greaney, A.J., Hilton, S.K., et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182(5), 1295-1310 (2020).
4. Kemp, S.A., Datir, R.P., Collier, D.A., et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70. bioRxiv 2020.12.14.422555 (2020).
5. Kemp, S.A., Collier, D.A., Datir, R., et al. Neutralising antibodies drive spike mediated SARS-CoV-2 evasion. medRxiv 2020.12.05.20241927 (2020).
6. Hoffmann, M., Kleine-Weber, H., and Pöhlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78(4), 779-84 (2020).
7. Peacock, T.P., Goldhill, D.H., Zhou, J., et al. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. bioRxiv 2020.09.30.318311 (2020).
8. Zhu, Y., Feng, F., Hu, G., et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. bioRxiv 2020.08.25.266775 (2020).
9. Zinzula, L. Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2. Biochem. Biophys. Res. Commun. (2020).
10. Young, B.E., Fong, S.-W., Chan, Y.-H., et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet 396(10251), 603-611 (2020).
11. Pond, S.L.K., Wilkison, E., Weaver, S., et al. A preliminary selection analysis of the South African V501.V2 SARS-CoV-2 clade. In: virological.org [Internet]. (2020). Available from: https://virological.org/t/a-preliminary-selection-analysis-of-the-south-african-v501-v2-sars-cov-2-clade/573
12. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020.12.21.20248640 (2020).
13. Greaney, A.J., Starr, T.N., Gilchuk, P., et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29(1), 44-57 (2021).
14. Faria, N.R., Claro, I.M., Candido, D., et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586
15. Pond, S.L.K., Wilkison, E., Weaver, S., et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585
16. Resende, P.C., Bezerra, J.F., de Vasconcelos, R.H.T., et al. Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. In: virological.org [Internet]. (2021). Available from: https://virological.org/t/spike-e484k-mutation-in-the-first-sars-cov-2-reinfection-case-confirmed-in-brazil-2020/584
17. Cherian, S., Potdar, V., Jadhav, S., et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv (2021).
Cayman Chemical
About UsManagement TeamCareersBuy Cayman GearIntellectual Property ProgramsContact UsConferences
Conference ScheduleContact Info
Cayman Chemical1180 East Ellsworth RoadAnn Arbor, Michigan 48108 USA